Clinical Trials Browser

Phase 2 × Anal Canal Carcinoma × Ipilimumab × Clear all

NCT02314169 2025-04-29

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms